prof. gill | the results of using the combination of cd19 car-t cells and ibrutinib in cll patients
Published 7 years ago • 547 plays • Length 3:58Download video MP4
Download video MP3
Similar videos
-
9:48
saar gill, md: combining car t-cell therapy with ibrutinib in cll patients
-
1:01
findings for cd19-targeted car t cells in combination with ibrutinib in cll
-
3:50
cll outcomes after cd19 car-t with ibrutinib
-
1:40
rationale for ibrutinib/car t-cell therapy combination in cll
-
1:29
combining ibrutinib with car-t cells: a promising therapeutic strategy in cll
-
0:47
durable responses after cd19 car-t plus ibrutinib in cll
-
1:09
results for the combination of nivolumab and ibrutinib in non-hodgkin lymphoma and cll
-
0:52
the potential of targeting non-malignant cells in the cll microenvironment
-
5:10
what is the role of car t-cell therapy in chronic lymphocytic leukemia (cll)?
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
2:04
the evolving role of car-t therapy in cll
-
5:01
combining car t-cell therapy with targeted drugs—can we improve efficacy in patients with r/r cll?
-
4:24
key questions in the field of cd19 car t-cell therapy
-
5:42
car t-cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia
-
0:55
dr. pinilla-ibarz on ibrutinib's efficacy in treating high-risk patients with cll
-
4:52
car-t cell therapies in cll
-
20:40
cll: treatment for btki progressors
-
2:53
highlights from the lymphoma and cll session
-
1:37
dr. wierda on using cd19-targeted car t cells in cll